Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy

Journal of Clinical Pathology

Volumn 50, Issue 5, 1997, Pages 384-388

  Colecchia, M ^a   Frigo, B ^a   Del Boca, C ^b   Guardamagna, A ^b   Zucchi, A ^c   Colloi, D ^b   Leopardi, O ^a  

^a MAGGIORE HOSPITAL   (Italy)

^b Division of Urology

^c Epidemiology Unit

Author keywords

Apoptosis; Nick end labelling; Prostatic cancer

Indexed keywords

FLUTAMIDE; LEUPRORELIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER HORMONE THERAPY; CLINICAL ARTICLE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0030912982     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.50.5.384     Document Type: Article

References (24)

1. Labrie F, Belanger A, Simard J, Labrie C, Dupont A. Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard firstline therapy. Cancer 1993;71:1059-67.
2. Fair WR, Aprikian A, Sogani P, Reuter V, Whitmore WF. The role of neoadjuvant hormonal manipulation in localized prostatic cancer. Cancer 1993;71(Suppl):1031-8.
3. Aprikian AG, Fair WR, Reuter VE, Sogani P, Herr H, Russo P, et al. Experience with neoadjuvant diethylstilboestrol and radical prostatectomy in patients with locally advanced prostate cancer. Br J Urol 1994;74:630-6.
4. Graham SD, Keane TE, Petros , Sanders WH. Perioperative hormonal therapy in locally advanced adenocarcinoma of the prostate. Cancer 1995;75:1969-71.
5. Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990;50:3748-53.
6. Kyprianou N. Apoptosis: therapeutic significance in the treatment of androgen-dependent and androgen-independent prostate cancer. World J Urol 1994;12:299-303.
7. Armas OA, Aprikian AG, Melamed J, Cordon-Cardo C, Cohen DW, Erlandson R, et al. Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol 1994;18:979-91.
8. Gleason DF, Mellinger GT and the VACURG. Prediction of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical staging. J Urol 1974;111:58-64.
9. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
10. Bursch W, Oberhammer F, Schulte-Herman R. Cell death by apoptosis and its protective role against disease. Trends Pharmacol Sci 1992;13:245-51.
11. Gorczyca W, Tuziak T, Kram A, Melamed MR, Darzynkiewicz Z. Detection of apoptosis-associated DNA strand breaks in fine-needle aspiration biopsies by in situ end labeling of fragmented DNA. Cytometry 1994;15:169-75.
12. Gorczyca W, Gong J, Darzynkiewicz Z. Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res 1993;53:1945-51.
13. Harriss DR, Savill J. Apoptosis and the prostate. Br J Urol 1995;75(Suppl 1):27-33.
14. Montironi R, Magi-Galluzzi C, Muzzonigro G, Prete E, Polito M, Fabris G. Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J Clin Pathol 1994;47:906-13.
15. Aihara M, Truong LD, Dunn JK, Wheeler TM, Scardino PT, Thompson TC. Frequency of apoptotic bodies positively correlates with Gleason grade in prostate cancer. Hum Pathol 1994;25:797-801.
16. Gaffney EF. The extent of apoptosis in different types of high grade prostatic carcinoma. Histopathology 1994;15: 169-75.
17. Westin P, Stattin P, Damber J-E, Bergh A. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumours. Am J Pathol 1995;146:1368-75.
18. Mellon K, Thompson S, Charlton RG, Marsh C, Robinson M, Lane DP, et al. p53, c-erb B-2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urol 1992;147:496-9.
19. Hall MC, Navone NM, Troncoso P, Pollack A, Zagars GK, von Eschenbach AC, et al. Frequency and characterization of p53 mutations in clinically localized prostate cancer. Urology 1995;45:470-5.
20. Aprikian AG, Sarkis AS, Fair WR, Zhang Z-F, Fuks Z, Cordon-Cardo C. Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcnioma. J Urol 1994;151:1276-80.
21. Ittmann M, Wieczorek R, Heller P, Dave A, Provet J, Krolewski J. Alterations in the p53 and mdm-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas. Am J Pathol 1994;145:287-93.
22. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, et al. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J Natl Cancer Inst 1993;85:1657-69.
23. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone refractory-human prostate cancers. Am J Pathol 1993;8:390-400.
24. Stewart BW. Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators. J Natl Cancer Inst 1994;86:1286-96.